益丰药房 - Financials

益丰药房 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	24.1B	22.6B	19.9B	15.3B	13.1B
Revenue Growth %	6.5%	13.6%	29.8%	16.6%	--
Total Revenue	24.1B	22.6B	19.9B	15.3B	13.1B
Cost Of Revenue	14.4B	14.0B	12.0B	9.1B	8.2B
+Gross Profit	9.7B	8.6B	7.9B	6.2B	5.0B
Gross Margin %	40.1%	38.2%	39.5%	40.3%	38.0%
Total Operating Cost	22.1B	20.7B	18.1B	14.1B	12.1B
Selling Expenses	6.2B	5.5B	4.9B	4.1B	3.2B
Admin Expenses	1.1B	962.0M	904.0M	657.0M	546.0M
Rd Expenses	33.9M	33.5M	25.3M	15.6M	8.3M
Finance Expenses	174.0M	86.2M	105.0M	115.0M	142.0M
+Operating Income	2.2B	2.1B	1.9B	1.3B	1.1B
Operating Margin %	9.2%	9.1%	9.5%	8.7%	8.6%
Non Operating Income	12.7M	12.7M	12.2M	9.9M	6.8M
Non Operating Expenses	34.1M	29.9M	20.3M	10.9M	12.9M
Investment Income	108.0M	42.4M	6.9M	34.4M	29.4M
Asset Disposal Income	49.9M	41.8M	23.2M	6.8M	320,600
Asset Impairment Loss	102.0M	72.6M	56.0M	40.7M	31.4M
Other Income	57.7M	76.1M	43.9M	62.1M	59.1M
Income Before Tax	2.2B	2.0B	1.9B	1.3B	1.1B
Income Tax	530.0M	457.0M	454.0M	347.0M	288.0M
+Net Income	1.7B	1.6B	1.4B	991.0M	839.0M
Net Margin %	6.9%	7.0%	7.2%	6.5%	6.4%
Net Income Attributable	1.5B	1.4B	1.3B	888.0M	744.0M
Minority Interest	124.0M	169.0M	162.0M	103.0M	95.9M
Eps Basic	1.26	1.17	1.26	1.25	1.08
Eps Diluted	1.24	1.17	1.25	1.24	1.08

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	3.6B	3.6B	4.1B	2.9B	3.4B
Trading Financial Assets	4.4B	1.6B	50.0M	152.0M	745.0M
Accounts Receivable	2.1B	2.1B	1.8B	1.1B	830.0M
Notes Receivable	--	--	--	--	--
Notes And Accounts Receivable	2.1B	2.1B	1.8B	1.1B	830.0M
Prepayments	303.0M	141.0M	225.0M	91.1M	96.8M
Inventory	4.5B	3.8B	3.6B	3.0B	2.2B
Total Current Assets	15.9B	12.1B	10.6B	7.9B	7.7B
Long Term Equity Investment	--	5.6M	5.2M	5.3M	5.3M
Fixed Assets	--	1.5B	1.2B	918.0M	577.0M
Fixed Assets Total	1.6B	1.5B	1.2B	918.0M	577.0M
Construction In Progress	--	175.0M	240.0M	359.0M	236.0M
Construction In Progress Total	229.0M	175.0M	240.0M	359.0M	236.0M
Intangible Assets	483.0M	471.0M	478.0M	389.0M	371.0M
Long Term Deferred Expenses	491.0M	496.0M	423.0M	372.0M	263.0M
Total Non Current Assets	12.1B	12.0B	10.5B	9.1B	7.7B
Total Assets	28.0B	24.1B	21.0B	17.1B	15.3B
Short Term Borrowings	30.0M	--	--	--	380.0M
Accounts Payable	2.0B	2.0B	1.7B	1.3B	1.1B
Advance Receipts	22.9M	16.0M	6.1M	7.0M	5.9M
Contract Liabilities	130.0M	80.2M	60.7M	41.1M	30.5M
Total Current Liabilities	12.6B	11.3B	9.7B	6.7B	5.9B
Long Term Borrowings	--	134.0M	229.0M	366.0M	628.0M
Total Non Current Liabilities	4.0B	2.4B	2.3B	2.4B	3.8B
Total Liabilities	16.6B	13.7B	11.9B	9.2B	9.7B
Paid In Capital	1.2B	1.0B	722.0M	719.0M	532.0M
Capital Reserve	3.7B	3.8B	4.1B	4.0B	2.6B
Surplus Reserve	326.0M	198.0M	132.0M	108.0M	92.2M
Retained Earnings	5.4B	4.8B	3.7B	2.7B	2.0B
Minority Equity	668.0M	643.0M	565.0M	383.0M	305.0M
Equity Attributable	10.7B	9.8B	8.6B	7.5B	5.4B
Total Equity	11.4B	10.4B	9.1B	7.9B	5.7B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	25.5B	23.7B	20.5B	16.0B	13.8B
Tax Refunds Received	--	--	--	--	256,500
Total Operating Cash Inflow	25.8B	24.1B	20.7B	16.2B	13.9B
Cash Paid For Goods	14.6B	13.3B	11.5B	9.7B	8.1B
Cash Paid To Employees	3.9B	3.7B	3.1B	2.6B	2.0B
Taxes Paid	1.3B	1.3B	1.1B	747.0M	772.0M
Total Operating Cash Outflow	21.5B	19.5B	16.8B	14.1B	11.6B
Operating Cash Flow	4.2B	4.6B	3.9B	2.1B	2.3B
Total Investing Cash Inflow	16.1B	3.7B	728.0M	2.3B	1.4B
Total Investing Cash Outflow	19.7B	6.7B	2.0B	2.8B	2.7B
Investing Cash Flow	-3.6B	-3.0B	-1.3B	-567.0M	-1.3B
Cash From Borrowings	30.0M	--	80.0M	142.0M	1.9B
Dividends And Interest Paid	951.0M	417.0M	316.0M	240.0M	176.0M
Debt Repayments	175.0M	84.4M	132.0M	847.0M	88.1M
Total Financing Cash Inflow	1.8B	17.0M	157.0M	142.0M	2.0B
Total Financing Cash Outflow	2.7B	2.1B	1.8B	2.3B	1.3B
Financing Cash Flow	-920.0M	-2.1B	-1.7B	-2.2B	714.0M
Net Change In Cash	-308.0M	-450.0M	991.0M	-602.0M	1.8B
Ending Cash Balance	2.2B	2.5B	2.9B	1.9B	2.5B
Capex	683.0M	740.0M	588.0M	828.0M	583.0M